Ultragenyx Pharmaceutical (GB:0LIF)
UK Market

Ultragenyx Pharmaceutical Stock Analysis & Ratings

GB:0LIF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$59.9
Average Volume (3M)150.00
Market Cap$4.19B
P/E RatioN/A
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Ultragenyx Pharmaceutical’s market cap?
    Ultragenyx Pharmaceutical’s market cap is $4.19B.
      What is Ultragenyx Pharmaceutical’s price target?
      The average price target for Ultragenyx Pharmaceutical is $113.13. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $146.00 ,the lowest forecast is $90.00. The average price target represents 88.86% Increase from the current price of $59.9.
        What do analysts say about Ultragenyx Pharmaceutical?
        Ultragenyx Pharmaceutical’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
          Ultragenyx Pharmaceutical’s upcoming earnings report date is Aug 04, 2022 which is in 75 days.
            How were Ultragenyx Pharmaceutical’s earnings last quarter?
            Ultragenyx Pharmaceutical released its earnings results on May 05, 2022. The company reported -$2.19 earnings per share for the quarter, missing the consensus estimate of -$1.781 by -$0.409.
              Is Ultragenyx Pharmaceutical overvalued?
              According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
                Does Ultragenyx Pharmaceutical pay dividends?
                Ultragenyx Pharmaceutical does not currently pay dividends.
                What is Ultragenyx Pharmaceutical’s EPS estimate?
                Ultragenyx Pharmaceutical’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Ultragenyx Pharmaceutical have?
                Ultragenyx Pharmaceutical has 69,930,000 shares outstanding.
                  What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
                  Ultragenyx Pharmaceutical reported an EPS of -$2.19 in its last earnings report, missing expectations of -$1.781. Following the earnings report the stock price went down -16.875%.
                    Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
                    Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Echo Street Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 234K.


                      Ultragenyx Pharmaceutical Stock Analysis

                      Smart Score
                      Price Target
                      ▲(88.86% Upside)
                      Strong Buy
                      The Ultragenyx Pharmaceutical stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Ultragenyx Pharmaceutical

                      Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

                      Similar Stocks
                      Price & Change
                      SAGE Therapeutics
                      Agios Pharma
                      Radius Health

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis